User login
TOPLINE:
not amenable to curative therapy, new data showed.
METHODOLOGY:
- Chemotherapy is the primary treatment in patients with stage IV (CRC) and unresectable metastases. It’s unclear whether primary tumor resection before chemotherapy prolongs survival.
- Among 393 patients with stage IV colon cancer and unresectable metastases enrolled in the and trials, 187 were randomly allocated to undergo primary tumor resection and 206 to upfront chemotherapy.
- The chemotherapy regimen was left up to the treating physician. Overall survival was the primary endpoint. Median follow-up time was 36.7 months.
TAKEAWAY:
- Median overall survival was 16.7 months with primary tumor resection and 18.6 months with upfront chemotherapy (P = .191).
- Comparable overall survival between the study groups was further confirmed on multivariate analysis (hazard ratio, 0.944; P = .65) and across all subgroups.
- Serious adverse events were more common with upfront chemo than surgery (18% vs 10%; P = .027), due mainly to a significantly higher incidence of GI-related events (11% vs 5%; P = .031).
- Overall, 24% of the primary tumor resection group did not receive any chemotherapy.
IN PRACTICE:
“The results of our study provide compelling data that upfront primary tumor resection in treatment-naive stage IV CRC not amenable for curative treatment does not prolong [overall survival]. A relatively low incidence of serious adverse events in patients with an intact primary tumor together with a considerable number of patients who did not receive any chemotherapy in the primary tumor resection group provides further arguments against resection of the primary tumor in this group of patients,” the authors of the combined analysis concluded.
SOURCE:
The study, with first author Nuh N. Rahbari, MD, University of Ulm, Ulm, Germany, was published online in the Journal of Clinical Oncology.
LIMITATIONS:
Neither study completed their planned patient accrual. Although both trials are nearly identical, differences in the individual study cohorts and trial implementation could have introduced bias. Tumor molecular profiling was not performed.
DISCLOSURES:
The study had no commercial funding. Disclosures for authors are available with the original article.
A version of this article appeared on Medscape.com.
TOPLINE:
not amenable to curative therapy, new data showed.
METHODOLOGY:
- Chemotherapy is the primary treatment in patients with stage IV (CRC) and unresectable metastases. It’s unclear whether primary tumor resection before chemotherapy prolongs survival.
- Among 393 patients with stage IV colon cancer and unresectable metastases enrolled in the and trials, 187 were randomly allocated to undergo primary tumor resection and 206 to upfront chemotherapy.
- The chemotherapy regimen was left up to the treating physician. Overall survival was the primary endpoint. Median follow-up time was 36.7 months.
TAKEAWAY:
- Median overall survival was 16.7 months with primary tumor resection and 18.6 months with upfront chemotherapy (P = .191).
- Comparable overall survival between the study groups was further confirmed on multivariate analysis (hazard ratio, 0.944; P = .65) and across all subgroups.
- Serious adverse events were more common with upfront chemo than surgery (18% vs 10%; P = .027), due mainly to a significantly higher incidence of GI-related events (11% vs 5%; P = .031).
- Overall, 24% of the primary tumor resection group did not receive any chemotherapy.
IN PRACTICE:
“The results of our study provide compelling data that upfront primary tumor resection in treatment-naive stage IV CRC not amenable for curative treatment does not prolong [overall survival]. A relatively low incidence of serious adverse events in patients with an intact primary tumor together with a considerable number of patients who did not receive any chemotherapy in the primary tumor resection group provides further arguments against resection of the primary tumor in this group of patients,” the authors of the combined analysis concluded.
SOURCE:
The study, with first author Nuh N. Rahbari, MD, University of Ulm, Ulm, Germany, was published online in the Journal of Clinical Oncology.
LIMITATIONS:
Neither study completed their planned patient accrual. Although both trials are nearly identical, differences in the individual study cohorts and trial implementation could have introduced bias. Tumor molecular profiling was not performed.
DISCLOSURES:
The study had no commercial funding. Disclosures for authors are available with the original article.
A version of this article appeared on Medscape.com.
TOPLINE:
not amenable to curative therapy, new data showed.
METHODOLOGY:
- Chemotherapy is the primary treatment in patients with stage IV (CRC) and unresectable metastases. It’s unclear whether primary tumor resection before chemotherapy prolongs survival.
- Among 393 patients with stage IV colon cancer and unresectable metastases enrolled in the and trials, 187 were randomly allocated to undergo primary tumor resection and 206 to upfront chemotherapy.
- The chemotherapy regimen was left up to the treating physician. Overall survival was the primary endpoint. Median follow-up time was 36.7 months.
TAKEAWAY:
- Median overall survival was 16.7 months with primary tumor resection and 18.6 months with upfront chemotherapy (P = .191).
- Comparable overall survival between the study groups was further confirmed on multivariate analysis (hazard ratio, 0.944; P = .65) and across all subgroups.
- Serious adverse events were more common with upfront chemo than surgery (18% vs 10%; P = .027), due mainly to a significantly higher incidence of GI-related events (11% vs 5%; P = .031).
- Overall, 24% of the primary tumor resection group did not receive any chemotherapy.
IN PRACTICE:
“The results of our study provide compelling data that upfront primary tumor resection in treatment-naive stage IV CRC not amenable for curative treatment does not prolong [overall survival]. A relatively low incidence of serious adverse events in patients with an intact primary tumor together with a considerable number of patients who did not receive any chemotherapy in the primary tumor resection group provides further arguments against resection of the primary tumor in this group of patients,” the authors of the combined analysis concluded.
SOURCE:
The study, with first author Nuh N. Rahbari, MD, University of Ulm, Ulm, Germany, was published online in the Journal of Clinical Oncology.
LIMITATIONS:
Neither study completed their planned patient accrual. Although both trials are nearly identical, differences in the individual study cohorts and trial implementation could have introduced bias. Tumor molecular profiling was not performed.
DISCLOSURES:
The study had no commercial funding. Disclosures for authors are available with the original article.
A version of this article appeared on Medscape.com.
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>167188</fileName> <TBEID>0C04EE0F.SIG</TBEID> <TBUniqueIdentifier>MD_0C04EE0F</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20240306T125800</QCDate> <firstPublished>20240306T132125</firstPublished> <LastPublished>20240306T132125</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20240306T132125</CMSDate> <articleSource/> <facebookInfo/> <meetingNumber/> <byline>Megan Brooks</byline> <bylineText>MEGAN BROOKS</bylineText> <bylineFull>MEGAN BROOKS</bylineFull> <bylineTitleText/> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>Resecting the primary colon tumor before chemotherapy does not improve overall survival compared with chemotherapy alone in patients with metastatic colon cance</metaDescription> <articlePDF/> <teaserImage/> <teaser>How did overall survival in patients receiving primary tumor resection compare with that of patients receiving upfront chemotherapy?</teaser> <title>Is Primary Tumor Resection Beneficial in Stage IV CRC?</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>oncr</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>mdsurg</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> <journalTitle/> <journalFullTitle/> <copyrightStatement>2018 Frontline Medical Communications Inc.,</copyrightStatement> </publicationData> <publicationData> <publicationCode>GIHOLD</publicationCode> <pubIssueName>January 2014</pubIssueName> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> <journalTitle/> <journalFullTitle/> <copyrightStatement/> </publicationData> </publications_g> <publications> <term canonical="true">31</term> <term>52226</term> </publications> <sections> <term>39313</term> <term canonical="true">27970</term> </sections> <topics> <term canonical="true">67020</term> <term>213</term> <term>270</term> <term>263</term> <term>337</term> <term>340</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Is Primary Tumor Resection Beneficial in Stage IV CRC?</title> <deck/> </itemMeta> <itemContent> <h2>TOPLINE:</h2> <p><span class="tag metaDescription">Resecting the primary colon tumor before chemotherapy does not improve overall survival compared with chemotherapy alone in patients with metastatic <a href="https://emedicine.medscape.com/article/277496-overview">colon cancer</a> </span>not amenable to curative therapy, new data showed.</p> <h2>METHODOLOGY:</h2> <ul class="body"> <li>Chemotherapy is the primary treatment in patients with stage IV (CRC) and unresectable metastases. It’s unclear whether primary tumor resection before chemotherapy prolongs survival.</li> <li>Among 393 patients with stage IV colon cancer and unresectable metastases enrolled in the and trials, 187 were randomly allocated to undergo primary tumor resection and 206 to upfront chemotherapy.</li> <li>The chemotherapy regimen was left up to the treating physician. Overall survival was the primary endpoint. Median follow-up time was 36.7 months.</li> </ul> <h2>TAKEAWAY:</h2> <ul class="body"> <li>Median overall survival was 16.7 months with primary tumor resection and 18.6 months with upfront chemotherapy (<em>P</em> = .191).</li> <li>Comparable overall survival between the study groups was further confirmed on multivariate analysis (hazard ratio, 0.944; <em>P </em>= .65) and across all subgroups.</li> <li>Serious adverse events were more common with upfront chemo than surgery (18% vs 10%; <em>P</em> = .027), due mainly to a significantly higher incidence of GI-related events (11% vs 5%; <em>P</em> = .031).</li> <li>Overall, 24% of the primary tumor resection group did not receive any chemotherapy.</li> </ul> <h2>IN PRACTICE:</h2> <p>“The results of our study provide compelling data that upfront primary tumor resection in treatment-naive stage IV CRC not amenable for curative treatment does not prolong [overall survival]. A relatively low incidence of serious adverse events in patients with an intact primary tumor together with a considerable number of patients who did not receive any chemotherapy in the primary tumor resection group provides further arguments against resection of the primary tumor in this group of patients,” the authors of the combined analysis concluded.</p> <h2>SOURCE:</h2> <p>The study, with first author Nuh N. Rahbari, MD, University of Ulm, Ulm, Germany, was <a href="https://ascopubs.org/doi/abs/10.1200/jco.23.01540?journalCode=jco">published online</a> in the <em>Journal of Clinical Oncology</em>.</p> <h2>LIMITATIONS:</h2> <p>Neither study completed their planned patient accrual. Although both trials are nearly identical, differences in the individual study cohorts and trial implementation could have introduced bias. Tumor molecular profiling was not performed.</p> <h2>DISCLOSURES:</h2> <p>The study had no commercial funding. Disclosures for authors are available with the original article.</p> <p> <em>A version of this article appeared on <span class="Hyperlink"><a href="https://www.medscape.com/viewarticle/primary-tumor-resection-beneficial-stage-iv-crc-2024a10004bf">Medscape.com</a></span>.</em> </p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>